Warning: UK E-liquids may Contain Dangerous Synthetic Drugs

Regulations by 2FIRSTS.ai
Feb.08.2024
Warning: UK E-liquids may Contain Dangerous Synthetic Drugs
Warning: Some e-liquids sold in the UK may contain illicit substances, including synthetic cannabinoids known as "spice."

Recently, health experts in Wales, UK issued a warning claiming that e-liquids being sold in the country may contain synthetic marijuana compounds known as "Spice". They argue that these illicit e-liquids have extremely potent medicinal effects and pose a danger to users who opt for counterfeit prescription drug e-cigarette products.

 

Some e-liquids consumed by UK consumers in their daily lives contain cannabis, CBD, or tetrahydrocannabinol (THC). Recently, WEDINOS, the only nationwide drug testing service in the UK, conducted tests and found that certain e-liquids being sold in the market also contain a potent synthetic drug known as synthetic cannabinoid receptor agonists (SCRAs), sometimes referred to as "spice." Based on these test results, the Welsh public health department has stated that some of these products being sold in the UK pose significant risks to consumers.

 

Synthetic cannabinoid receptor agonists (SCRAs) are a group of compounds associated with significant health issues, ranging from respiratory difficulties to psychiatric episodes. The latest data from WEDINOS, an organization, reveals that out of the 196 liquid samples submitted to them in 2023, 75 samples (almost one-third) contained one or more SCRA compounds.

 

These samples were purchased in the form of cannabis, CBD, or THC e-liquids. Among the number of hospitalizations due to illicit drugs, opioids are the most prevalent, followed by cannabis and synthetic cannabinoids such as Spice. Opioids also remain the most likely type of drug to be associated with drug-related deaths.

 

Experts from the agency have expressed concern over a significant increase in the number of counterfeit prescription drug samples they have received, which have been contaminated with potentially hazardous substances. They have also frequently detected the presence of benzodiazepines, a class of drugs commonly purchased as prescription medication, such as diazepam and hydrocodone.

 

These highly concentrated synthetic opioid medications can pose a threat to life, and there is a significant risk of overdosing. Last year, WEDINOS received 90 samples containing nitrous nitrogen drugs, with nearly 50% purchased under the mistaken belief of being an anti-anxiety medication called diazepam.

 

Professor Rick Lines, the Head of Drug Abuse at the Welsh Public Health Department, has highlighted the need to recognize the increased risk of medication overdose associated with high-concentration drugs. "Our concern is that people who purchase e-cigarettes online may not actually be receiving what they believe they are getting," he cautioned.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

NYC makers turn discarded disposable vapes into “Vape Synth” mini digital instruments
NYC makers turn discarded disposable vapes into “Vape Synth” mini digital instruments
The report says disposable vapes are sold at more than 11 million units per month and often end up in landfills after flavored nicotine juice runs out, along with lithium-ion batteries, microcontrollers, and LEDs, increasing the risk of waste fires. A New York City maker trio known as Paper Bag Team has built “Vape Synth” by cracking open spent Elf Bar cartridges—specifically the EB BC5000—and hacking them into tiny digital instruments.
Feb.12 by 2FIRSTS.ai
Walgreens Brings Vapes Back to Some U.S. Stores; Juul Says It’s in or Near 6,000 Locations
Walgreens Brings Vapes Back to Some U.S. Stores; Juul Says It’s in or Near 6,000 Locations
Walgreens has begun selling vape products again in some U.S. stores, marking a notable reversal after the chain pulled vapes from shelves in 2019 amid concerns over youth use and health risks. Juul says it is expanding across thousands of Walgreens locations, and NJOY also lists Walgreens stores as retailers.
Jan.26 by 2FIRSTS.ai
USITC Launches Section 337 Probe Into Disposable and Closed-System ENDS, Involving 16 Companies
USITC Launches Section 337 Probe Into Disposable and Closed-System ENDS, Involving 16 Companies
The U.S. International Trade Commission (USITC) voted to institute a Section 337 investigation into certain disposable and other closed-system electronic nicotine delivery systems (ENDS) devices and components thereof (Inv. No. 337-TA-1486). The investigation stems from a complaint filed on January 13, 2026 by R.J. Reynolds entities based in Winston-Salem, North Carolina, supplemented on February 3, 2026.
Mar.05 by 2FIRSTS.ai
Product | OXVA launches SlimStick X in Europe and the U.S., shifting from pre-filled to open-system refilling
Product | OXVA launches SlimStick X in Europe and the U.S., shifting from pre-filled to open-system refilling
OXVA has recently launched its new e-cigarette, the SlimStick X. Unlike its predecessor, the SlimStick, which used a pre-filled pod system, the SlimStick X adopts an open-system refillable design, featuring a 2ml pod, a 1.0Ω coil, and a 1400mAh battery. The product has entered online retail channels in markets including the United States, the United Kingdom, Greece, and Spain, with a price of about $23.99.
Mar.06 by 2FIRSTS.ai
Product | Detachable Battery + Dual-Battery System: RAZ VUE 50K Launches on U.S. Online Vape Channels
Product | Detachable Battery + Dual-Battery System: RAZ VUE 50K Launches on U.S. Online Vape Channels
RAZ has recently launched the RAZ VUE 50K on U.S. online vape channels, positioning it as the brand’s first disposable vape featuring a detachable battery. The device uses a dual-battery setup—an integrated 420mAh battery in the pod paired with a reusable 900mAh power bank—and is rated for up to approximately 50,000 puffs in Normal Mode.
Jan.16 by 2FIRSTS.ai
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.
Feb.11